Tacere gets seed funding to develop Hepatitis C treatment
Tacere Therapeutics, a San Jose biotech start-up has raised seed financing to develop treatments for serious infectious diseases.
The financing came from from Hokkaido Venture Capital.
The company is developing a drug called “TT-033i,” for the treatment of Hepatitis C (HCV). See details here.
Next Story: Mohr Davidow's Sam Jadallah shifts to pursue late-stage deals
Previous Story: Alternative fuel co., Amyris, gets $20M from Khosla Ventures, others
VB Writers
Ben PopperEast Coast Editor
Dean TakahashiLead Writer, GamesBeat
Devindra HardawarNational Editor, MobileBeat Lead
Dylan TweneyExecutive Editor
ShoeEditor-in-Chief, GamesBeat
Heather KellySenior Editor
Jennifer Van GroveWriter
Jolie O'DellWriter
Matt MarshallFounder & Editor-in-Chief
Meghan KellyWriter
Sarah MitroffEditorial Assistant
Sean LudwigWriter
Sebastian HaleyReviews Editor, GamesBeat
Tom CheredarWriter
Ciara ByrneContributor
Julia PlevinContributor
Lindsey ComptonContributor
